BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10076573)

  • 1. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
    Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
    Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.
    Bungo M; Fujiwara Y; Kasahara K; Nakagawa K; Ohe Y; Sasaki Y; Irino S; Saijo N
    Cancer Res; 1990 May; 50(9):2549-53. PubMed ID: 2158392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
    Masumoto N; Nakano S; Fujishima H; Kohno K; Niho Y
    Int J Cancer; 1999 Mar; 80(5):731-7. PubMed ID: 10048975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
    Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
    Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.
    Oshita F; Fujiwara Y; Saijo N
    J Cancer Res Clin Oncol; 1992; 119(1):28-34. PubMed ID: 1400562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
    Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
    Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP).
    Ohmori T; Nishio K; Ohta S; Kubota N; Adachi M; Komiya K; Saijo N
    Int J Cancer; 1994 Apr; 57(1):111-6. PubMed ID: 8150528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.
    Sugimoto Y; Ohe Y; Nishio K; Ohmori T; Morikage T; Fujiwara Y; Saijo N
    Br J Cancer; 1992 Jun; 65(6):857-64. PubMed ID: 1319727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines.
    Bando T; Kasahara K; Shibata K; Nakatsumi Y; Fujimura M; Matsuda T
    Anticancer Res; 1994; 14(6B):2727-30. PubMed ID: 7872708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.
    Morikage T; Ohmori T; Nishio K; Fujiwara Y; Takeda Y; Saijo N
    Cancer Res; 1993 Jul; 53(14):3302-7. PubMed ID: 8391922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP.
    Nishio K; Morikage T; Kubota N; Ohmori T; Takeda Y; Fujiwara Y; Miki K; Abe K; Saijo N
    Jpn J Cancer Res; 1992 Jul; 83(7):754-60. PubMed ID: 1325432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
    Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
    Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
    J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line.
    Nakagawa M; Nomura Y; Kohno K; Ono M; Mizoguchi H; Ogata J; Kuwano M
    J Urol; 1993 Dec; 150(6):1970-3. PubMed ID: 8230547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.